Elanix Biotechnologies AG

WKN: A0WMJQ
ISIN: DE000A0WMJQ4
Land: Deutschland

Nachricht vom 22.07.2019 | 10:17

Elanix Biotechnologies AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Elanix Biotechnologies AG

22.07.2019 / 10:17
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Elanix Biotechnologies AG
Street:	c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
Postal code:	60314
City:	Frankfurt am Main Germany
Legal Entity Identifier (LEI):	391200SYNFFL0NPAJK90

2. Reason for notification

	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
X	Other reason: Termination of the voting right agreement

3. Details of person subject to the notification obligation

Natural person (first name, surname): Anthony De Buys Rossingh
Date of birth: 22 Sep 1967

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

5. Date on which threshold was crossed or reached:

18 Dec 2018

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	1.76 %	0 %	1.76 %	8.080.902
Previous notification	19.35 %	0 %	19.35 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A0WMJQ4	142592	0	1.76 %	0 %
Total	142592		1.76 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
				%
		Total		%

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
					%
			Total		%

8. Information in relation to the person subject to the notification obligation

X	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

16 Jul 2019

22.07.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Elanix Biotechnologies AG
	c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
	60314 Frankfurt am Main
	Germany
Internet:	www.elanixbiotechnologies.com


End of News	DGAP News Service

Kurschart

Kursdetails anzeigen

Interaktiv

malformed JSON string, neither array, object, number, string or atom, at character offset 9 ["identify.exe: `%s' (..."] at E:\public_html\IRPages2\cgi-bin/0312/lib/user_functions_subs/getCompanyPictures.pl line 43

Content-type: text/html; charset=utf-8

Weblinks

DGAP-Watchlist

zur Registrierung

Übersicht Indizes

weitere Indizes

Weitere News

weitere News anzeigen

GBC-Fokusbox

Fonds Research 2019: Dt. Mittelstandsanleihen FONDS bietet attraktive Anlagemöglichkeit

Auch 2019 hat die GBC AG unter der Vielzahl an Publikumsfonds neun „Fonds Champions“ herausgefiltert. Darunter den Deutsche Mittelstandsanleihen FONDS (ISIN: LU0974225590), der eine qualitätsorientierte Strategie verfolgt und eine vielversprechende Anlagemöglichkeit in den deutschen Mittelstand bietet. Insbesondere vor dem Hintergrund des aktuellen Niedrigzinsniveaus sehen wir den Fonds als gute Chance, um attraktive Renditen zu erwirtschaften und dies verbunden mit einer traditionell niedrigen Fonds-Volatilität. Wir vergeben 5 von 5 GBC-Falken ein.

Zur Studie